Therapeutic monoclonal antibodies

NovImmmune is committed to innovation by discovering and developing therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders.

Founded in 1998
Total money raised: $155.4M


Phone: +41 22 839 71 41

Updated on Dec 17, 2010
NovImmune at CrunchBase
Jack Barbut CEO
Penny Ward CMO
Arnd Christ CFO
Marie Kosco-Vilbois CSO

December, 2010

NovImmune raised $20.6M in a Series B round from BZ Bank

NovImmune raises additional CHF 20 million

July, 2010

NovImmune inks deal, eyes possible IPO

May, 2009

NovImmune raised $54.8M in a Series D round from BZ Bank, Novartis Venture Fund, LODH Immunology Fund, Varuma AG, Pictet Private Equity Investors S.A., Ingro Finanz AG, and Aravis Ventures

NovImmune, SA: Series C $54.8M

June, 2006

NovImmune raised $53M in a Series C round from BZ Bank

Company History

February, 2005

NovImmune raised $13M in a Series B round

Company History

May, 2000

NovImmune raised $14M in a Series A round from Novartis Venture Fund and LODH Immunology Fund

Company History


NovImmune was founded in 1998